# US 2024/0002955 A1 · Methods for Estimating Microbial Density in Specimens by Measurement of Ribosomal RNA

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002955 A1
- Document ID: US20240002955A1
- Status: Published application
- Kind: A1
- Application number: 18/369,022
- Filed: 2023-09-15
- Published: 2024-01-04
- Earliest claimed: 2018-05-14
- Assignees: MicrobeDX Inc.; The Regents of the University of California
- Applicants: MicrobeDX, Inc.; The Regents of the University of California
- Inventors: Bernard Churchill; Scott Adam Churchman; David Arnold Haake; Colin Wynn Halford; Roger Knauf; Gabriel Monti; Victoria Scott
- Web page: https://patentgrep.com/patent/US20240002955A1

## CPC

- C12Q 1/689: for bacteria
- C12Q 1/06: Quantitative determination
- C12Q 1/6888: for detection or identification of organisms
- G01N 2800/26: Infectious diseases, e.g. generalised sepsis
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A method of determining a bacterial density in a specimen may include the steps of: (a) conducting an RNA assay on the specimen to determine a microbial rRNA concentration, wherein the microbial rRNA concentration is defined as the number of rRNA molecules per volume of the specimen; and (b) converting the rRNA concentration to a bacterial density value.

## Claims

### Claim 1

A method of determining a bacterial density value in a specimen, the method comprising:
(a) obtaining a specimen to be analyzed;
(b) conducting an RNA assay on the specimen including the steps of:
i) lysing the specimen to release bacterial rRNA using at least mechanical lysis;
ii) neutralizing the released rRNA;
iii) hybridizing the released rRNA with capture and detector probes to form one or more capture probe-rRNA-detector probe complexes; and
iv) detecting the capture probe-rRNA-detector probe complexes;
to determine a bacterial rRNA concentration in the specimen, wherein the bacterial rRNA concentration is defined as a number of rRNA molecules per volume of the specimen;
(c) converting the bacterial rRNA concentration to a bacterial density value; and
(d) displaying the bacterial density value to a user via a user display apparatus.

### Claim 2 (depends on 1)

The method of claim 1, wherein a pre-determined translation function is used to convert the bacterial rRNA concentration to the bacterial density value.

### Claim 3 (depends on 1)

The method of claim 1, the method comprising a further step of:
outputting the bacterial density value in a format that is useful for determining a dilution factor for a phenotypic antimicrobial susceptibility test.

### Claim 4 (depends on 1)

The method described in claim 1, wherein the specimen comprises at least one of a biological material and a culture of biological material.

### Claim 5 (depends on 1)

The method of claim 1, wherein the bacterial rRNA concentration is determined by steps comprising:
(a) processing the bacterial rRNA to obtain an rRNA signal, wherein the rRNA signal is determined using an electrochemical sensor platform, an optical platform, or a qRT-PCR, wherein the optical platform comprises at least one of an ELISA, magnetic beads, and a capture probe array;
(b) taking the log of the rRNA signal to obtain an rRNA signalLOG; and
(c) comparing the rRNA signalLOG with a positive control to determine the bacterial rRNA concentration of the specimen.

### Claim 6 (depends on 1)

The method of claim 1, wherein a pre-determined correlation is used to convert the bacterial rRNA concentration to the bacterial density value.

### Claim 7 (depends on 1)

The method of claim 1, wherein the specimen is provided by or taken from a mammal.

### Claim 8 (depends on 1)

The method of claim 1, wherein the specimen is a clinical specimen and wherein steps a) and b) are conducted directly on the clinical specimen.

### Claim 9 (depends on 8)

The method of claim 8, wherein the clinical specimen comprises a biological material, and the biological material comprises at least one of urine, blood, blood culture, serum, plasma, saliva, tears, gastric fluids, digestive fluids, stool, mucus, sputum, sweat, earwax, oil, semen, vaginal fluid, glandular secretion, breast milk, synovial fluid, pleural fluid, lymph fluid, amniotic fluid, feces, cerebrospinal fluid, wounds, burns, tissue homogenates and an inoculum derived therefrom that is generated during conventional laboratory testing procedures.

### Claim 10

A method of determining if a subject has an infection, comprising
(a) conducting a rRNA assay on a clinical specimen from the subject including the steps of:
i) lysing the specimen to release bacterial rRNA using at least mechanical lysis;
ii) neutralizing the released rRNA;
iii) hybridizing the released rRNA with capture and detector probes to form one or more capture probe-rRNA-detector probe complexes; and
iv) detecting the capture probe-rRNA-detector probe complexes;
to determine a bacterial rRNA concentration, wherein the bacterial rRNA concentration is defined as a number of rRNA molecules per volume of the specimen;
(b) converting the bacterial rRNA concentration to the bacterial density value and displaying the bacterial density value to a user via a user display; and
(c) determining if the subject has the infection by comparing the bacterial density value with a predetermined infection threshold value of the subject related to the clinical specimen.

### Claim 11 (depends on 10)

The method of claim 10, wherein a pre-determined translation function based on a known correlation between an actual rRNA concentration and a bacterial density is used to convert the bacterial rRNA concentration to the bacterial density value.

### Claim 12 (depends on 10)

The method of claim 10, wherein the infection is likely if the bacterial density value is greater than or equal to the infection threshold value.

### Claim 13 (depends on 10)

The method of claim 10, wherein an infection is not likely if the bacterial density value is less than the infection threshold value.

### Claim 14 (depends on 10)

The method of claim 10, wherein the clinical specimen is obtained from a mammal.

### Claim 15 (depends on 10)

The method of claim 10, wherein the clinical specimen comprises at least one of urine, blood, blood culture, serum, plasma, saliva, tears, gastric fluids, digestive fluids, stool, mucus, sputum, sweat, earwax, oil, semen, vaginal fluid, glandular secretion, breast milk, synovial fluid, pleural fluid, lymph fluid, amniotic fluid, feces, cerebrospinal fluid, wounds, burns, tissue homogenates and an inoculum derived therefrom that is generated during conventional laboratory testing procedures.

### Claim 16

A method of determining a dilution factor of a clinical specimen to use in a direct-from-specimen phenotypic antimicrobial susceptibility test, the method comprising:
(a) conducting a rRNA assay on the clinical specimen to determine a bacterial rRNA concentration, wherein the bacterial rRNA concentration is defined as a number of rRNA molecules per volume of the specimen; and
(b) converting the bacterial rRNA concentration to a bacterial density value; and
(c) comparing the bacterial density value to a target inoculation concentration for use in a phenotypic antimicrobial susceptibility test, wherein
if the bacterial density value is greater than the target inoculation concentration then further including the step of diluting the clinical specimen so that the bacterial density value is equal to or less than the target inoculation concentration before conducting the phenotypic antimicrobial susceptibility test, or
if the bacterial density value is less than the target inoculation concentration then further including the step of conducting the phenotypic antimicrobial susceptibility test without diluting the clinical specimen.

### Claim 17 (depends on 16)

The method of claim 16, wherein the clinical specimen is provided by or taken from a mammal.

### Claim 18 (depends on 16)

The method of claim 16, wherein the clinical specimen comprises a biological material, and wherein the biological material comprises at least one of urine, blood, serum, plasma, saliva, tears, gastric fluids, digestive fluids, stool, mucus, sputum, sweat, earwax, oil, semen, vaginal fluid, glandular secretion, breast milk, synovial fluid, pleural fluid, lymph fluid, amniotic fluid, feces, cerebrospinal fluid, wounds, burns, tissue homogenates and an inoculum derived therefrom that is generated during conventional laboratory testing procedures.
